Gregory R Stettler1, Ernest E Moore2, Geoffrey R Nunns1, Jim Chandler3, Erik Peltz1, Christopher C Silliman4, Anirban Banerjee1, Angela Sauaia5. 1. Department of Surgery, University of Colorado, Aurora, Colorado. 2. Department of Surgery, Denver Health Medical Center, Denver, Colorado. Electronic address: ernest.moore@dhha.org. 3. Department of Surgery, Denver Health Medical Center, Denver, Colorado. 4. Department of Pediatrics, University of Colorado, Aurora, Colorado; Bonfils Blood Center, Denver, Colorado. 5. Department of Surgery, University of Colorado, Aurora, Colorado; University of Colorado School of Public Health, University of Colorado, Aurora, Colorado.
Abstract
BACKGROUND: Goal-directed hemostatic resuscitation based on thrombelastography has a survival benefit compared to conventional coagulation assays. While thrombelastography transfusion thresholds for patients at risk for massive transfusion (MT) have been defined, similar cutoffs do not exist for the other commonly used viscoelastic assay, rotational thromboelastometry (ROTEM). The purpose of this study was to develop ROTEM blood product thresholds in patients at risk for MT. METHODS: ROTEM was assessed in trauma activation patients admitted from 2010 to 2016 (n = 222). Receiver operating characteristic curve analyses were performed to test the predictive performance of ROTEM measurements in patients requiring MT. The Youden Index defined optimal thresholds for ROTEM-based resuscitation. RESULTS: Patients who required MT (n = 37, 17%) were more severely injured. EXTEM clotting time (CT) was longer in patients with MT compared to non-MT (87 versus 64 s, P < 0.0001). EXTEM angle was shallower in MT patients compared to non-MT (54° versus 69°, P < 0.0001). Clot amplitude after 10 min (CA10) was less in MT compared to non-MT patients (30.5 versus 50 mm, P < 0.0001). Clot lysis index 60 min (CLI60) was lower in patients who had MT than non-MT (47 versus 94%, P = 0.0006). EXTEM CT yielded an area under the receiver operating characteristic curve (AUROC) = 0.7116 and a cut point of >78.5 s. EXTEM angle had an AUROC = 0.865 and a cut point of <64.5°. EXTEM CA10 had an AUROC = 0.858, with a cut point of <40.5 mm. CLI60 had an AUROC = 0.6788 with a cut point at <74%. CONCLUSIONS: We have identified ROTEM thresholds for transfusion of blood components in severely injured patients requiring an MT. Based on our analysis, we propose plasma transfusion for EXTEM CT > 78.5 s, fibrinogen for angle <64.5°, platelet transfusion for CA10 < 40.5 mm, and antifibrinolytics for CLI60 < 74%.
BACKGROUND: Goal-directed hemostatic resuscitation based on thrombelastography has a survival benefit compared to conventional coagulation assays. While thrombelastography transfusion thresholds for patients at risk for massive transfusion (MT) have been defined, similar cutoffs do not exist for the other commonly used viscoelastic assay, rotational thromboelastometry (ROTEM). The purpose of this study was to develop ROTEM blood product thresholds in patients at risk for MT. METHODS: ROTEM was assessed in trauma activation patients admitted from 2010 to 2016 (n = 222). Receiver operating characteristic curve analyses were performed to test the predictive performance of ROTEM measurements in patients requiring MT. The Youden Index defined optimal thresholds for ROTEM-based resuscitation. RESULTS:Patients who required MT (n = 37, 17%) were more severely injured. EXTEM clotting time (CT) was longer in patients with MT compared to non-MT (87 versus 64 s, P < 0.0001). EXTEM angle was shallower in MT patients compared to non-MT (54° versus 69°, P < 0.0001). Clot amplitude after 10 min (CA10) was less in MT compared to non-MT patients (30.5 versus 50 mm, P < 0.0001). Clot lysis index 60 min (CLI60) was lower in patients who had MT than non-MT (47 versus 94%, P = 0.0006). EXTEM CT yielded an area under the receiver operating characteristic curve (AUROC) = 0.7116 and a cut point of >78.5 s. EXTEM angle had an AUROC = 0.865 and a cut point of <64.5°. EXTEM CA10 had an AUROC = 0.858, with a cut point of <40.5 mm. CLI60 had an AUROC = 0.6788 with a cut point at <74%. CONCLUSIONS: We have identified ROTEM thresholds for transfusion of blood components in severely injured patients requiring an MT. Based on our analysis, we propose plasma transfusion for EXTEM CT > 78.5 s, fibrinogen for angle <64.5°, platelet transfusion for CA10 < 40.5 mm, and antifibrinolytics for CLI60 < 74%.
Authors: Max V Wohlauer; Ernest E Moore; Scott Thomas; Angela Sauaia; Ed Evans; Jeffrey Harr; Christopher C Silliman; Victoria Ploplis; Francis J Castellino; Mark Walsh Journal: J Am Coll Surg Date: 2012-05 Impact factor: 6.113
Authors: Peter M Einersen; Ernest E Moore; Michael P Chapman; Hunter B Moore; Eduardo Gonzalez; Christopher C Silliman; Anirban Banerjee; Angela Sauaia Journal: J Trauma Acute Care Surg Date: 2017-01 Impact factor: 3.313
Authors: Bhiken I Naik; Thomas N Pajewski; David I Bogdonoff; Zhiyi Zuo; Pamela Clark; Abdullah S Terkawi; Marcel E Durieux; Christopher I Shaffrey; Edward C Nemergut Journal: J Neurosurg Spine Date: 2015-05-22
Authors: Gregory R Stettler; Ernest E Moore; Geoffrey R Nunns; Marguerite Kelher; Anirban Banerjee; Christopher C Silliman Journal: J Surg Res Date: 2020-12-02 Impact factor: 2.192
Authors: Ernest E Moore; Hunter B Moore; Lucy Z Kornblith; Matthew D Neal; Maureane Hoffman; Nicola J Mutch; Herbert Schöchl; Beverley J Hunt; Angela Sauaia Journal: Nat Rev Dis Primers Date: 2021-04-29 Impact factor: 65.038
Authors: Mark Walsh; Ernest E Moore; Hunter B Moore; Scott Thomas; Hau C Kwaan; Jacob Speybroeck; Mathew Marsee; Connor M Bunch; John Stillson; Anthony V Thomas; Annie Grisoli; John Aversa; Daniel Fulkerson; Stefani Vande Lune; Lucas Sjeklocha; Quincy K Tran Journal: J Clin Med Date: 2021-01-17 Impact factor: 4.241
Authors: Nicole P Juffermans; Mathijs R Wirtz; Kirsten Balvers; Kjersti Baksaas-Aasen; Susan van Dieren; Christine Gaarder; Paul A Naess; Simon Stanworth; Pär I Johansson; Jakob Stensballe; Marc Maegele; J C Goslings; Karim Brohi Journal: J Thromb Haemost Date: 2019-02-17 Impact factor: 5.824
Authors: James H Lantry; Phillip Mason; Matthew G Logsdon; Connor M Bunch; Ethan E Peck; Ernest E Moore; Hunter B Moore; Matthew D Neal; Scott G Thomas; Rashid Z Khan; Laura Gillespie; Charles Florance; Josh Korzan; Fletcher R Preuss; Dan Mason; Tarek Saleh; Mathew K Marsee; Stefani Vande Lune; Qamarnisa Ayoub; Dietmar Fries; Mark M Walsh Journal: J Clin Med Date: 2022-01-12 Impact factor: 4.241